Hancock Whitney’s Dicerna Pharmaceuticals, Inc. DRNA Stock Holding History

Hancock Whitney’s Portfolio DRNA Stock Details DRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-15,908	Closed	-$321K	–	703
2021 Q3	$321K	Sell	15,908 -32,898	-67%	-$908K	0.01%	556
2021 Q2	$1.82M	Sell	48,806 -2,091	-4%	-$64.1K	0.06%	300
2021 Q1	$1.3M	Buy	50,897 +12,802	+34%	+$327K	0.04%	361
2020 Q4	$839K	Sell	38,095 -10,496	-22%	-$231K	0.03%	415
2020 Q3	$874K	Sell	48,591 -595	-1%	-$12.3K	0.03%	395
2020 Q2	$1.25M	Sell	49,186 -6,726	-12%	-$145K	0.05%	332
2020 Q1	$1.03M	Sell	55,912 -11,750	-17%	-$228K	0.04%	364
2019 Q4	$1.49M	Buy	+67,662	New	+$1.36M	0.05%	369

Other funds holding DRNA

CAM

Close Asset Management London, United Kingdom $3.69B AUM 21.62% 1-Year Est. Return

Hancock Whitney's DRNA Position: Q4 2021 in Review

Hancock Whitney sold out of Dicerna Pharmaceuticals, Inc. (DRNA) in Q4 2021, closing a stake of 15,908 shares — an estimated $321K sold.

Hancock Whitney first reported a position in DRNA in Q4 2019 and held it in 8 quarters. The position peaked at $1.82M in Q2 2021. 1 fund tracked by Wall St. Rank holds DRNA as of Q4 2021.

Hancock Whitney reported no remaining Dicerna Pharmaceuticals, Inc. position as of Q4 2021 after selling out during the quarter.
Hancock Whitney sold 15,908 Dicerna Pharmaceuticals, Inc. shares in Q4 2021, an estimated $321K.
Hancock Whitney first reported a position in Dicerna Pharmaceuticals, Inc. in Q4 2019 and held it in 8 quarters.
Hancock Whitney's Dicerna Pharmaceuticals, Inc. position peaked at $1.82M in Q2 2021.
1 fund tracked by Wall St. Rank held Dicerna Pharmaceuticals, Inc. as of Q4 2021.

Based on Hancock Whitney's 13F filing for Q4 2021, filed 25 Jan 2022.